Filing Flows › Cardiff Oncology (CRDF) › Q4 2025
Cardiff Oncology (CRDF) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 24, 2026
Cardiff Oncology (CRDF) reported revenue of $243K for the fourth quarter 2025 (Q4 2025), +61% from a year earlier and +102% from the quarter before.
Cardiff Oncology, Q4 2025: revenue $243K (+61% year over year), net loss $7.2M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $243K | +102% | +61% |
| Operating profit | −$7.8M | — | — |
| Net earnings | −$7.2M | — | — |
| Operating cash flow | −$6.0M | — | — |
What changed
Revenue was $243K in Q4 2025, up 61% year over year and up 102% from the previous quarter.
Operating costs exceeded revenue by $7.8M, an operating margin of -3221.0%. Total costs fell 37% while revenue rose 61%. The quarter ended with a net loss of $7.2M, narrower than the previous quarter's $11.3M loss.
Operating cash flow was −$6.0M. Non-cash charges added back $88K of depreciation and amortization and $1.3M of share-based compensation.
Questions
What was Cardiff Oncology's revenue in the fourth quarter 2025?
Cardiff Oncology (CRDF) reported revenue of $243K for the fourth quarter 2025 (Q4 2025), +61% from a year earlier and +102% from the quarter before.
Source: Cardiff Oncology 10-K on SEC EDGAR.